Clinical trial
A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With…
NCT00157872 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00157872 |
|---|---|
| Title | A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231) |
| Official title | A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | MK0966, rofecoxib, Comparator: naproxen tablet 500 mg |
| Enrollment | 150 |
| Start date | Jan 7, 2004 |
| Primary completion | Jul 5, 2004 |
| Completion | Sep 19, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | May 25, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: